

Biotin anti-mouse/human CD11b Antibody

Catalog# / Size	101203 / 50 µg 101204 / 500 µg
Clone	M1/70
Regulatory Status	RUO
Other Names	αM integrin, Mac-1, Mo1, CR3, Ly-40, C3biR, ITGAM
Isotype	Rat IgG2b, κ
Description	CD11b is a 170 kD glycoprotein also known as αM integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

Product Details

Verified Reactivity	Mouse, Human, Cynomolgus, Rhesus
Reported Reactivity	Chimpanzee, Baboon, Rabbit
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	C57BL/10 splenocytes
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 ⁶ cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes	Clone M1/70 has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F). Additional reported applications (for relevant formats of this clone) include: immunoprecipitation ^{1,4} , <i>in vitro</i> blocking ^{3,9,12} , depletion ^{2,8} , immunofluorescence microscopy ^{6,7,10} , immunohistochemistry of acetone-fixed frozen sections ^{5,11-13} , and spatial biology (IBEX) ^{35,36} . For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 101248).

Application References

1. Springer T, *et al.* 1978. *Eur. J. Immunol.* 8:539. (IP)
2. Ault K and Springer T. 1981. *J. Immunol.* 126:359. (Deplete)
3. Springer TA, *et al.* 1982. *Immunol. Rev.* 68:171. (Block)
4. Ho MK and Springer TA. 1983. *J. Biol. Chem.* 258:2766. (IP)
5. Flotte TJ, *et al.* 1983. *Am. J. Pathol.* 111:112. (IHC)
6. Noel GJ, *et al.* 1990. *J. Clin. Invest.* 85:208. (IF)
7. Allen LA and Aderem A. 1996. *J. Exp. Med.* 184:627 (IF)
8. D'Amico A and Wu L. 2003. *J. Exp. Med.* 198:293. (Deplete)
9. Brickson SJ, *et al.* 2003. *Appl Physiol.* 95:969. (Block)
10. Clatworthy MR and Smith KG. 2004. *J. Exp. Med.* 199:717. (IF)

11. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
12. Zhang Y, *et al.* 2002. *J. Immunol.* 168:3088. (IHC)
13. Iwasaki A and Kelsall BL. 2001. *J. Immunol.* 166:4884 (IHC, FC)
14. Tailleux L. 2003. *J. Exp. Med.* 197:121. (Block, FC)
15. Olver S, *et al.* 2006. *Cancer Research* 66:571. (FC)
16. Tan SL, *et al.* 2006. *J. Immunol.* 176:2872. (FC) [PubMed](#)
17. Ponomarev ED, *et al.* 2006. *J. Immunol.* 176:1402. (FC)
18. Dzhagalov I, *et al.* 2007. *Blood* 109:1620. (FC)
19. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
20. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
21. Napimoga MH, *et al.* 2008. *J. Immunol.* 180:609. [PubMed](#)
22. Elqaraz-Carmon V, *et al.* 2008. *J. Lipid. Res.* 49:1894. [PubMed](#)
23. Kim DD, *et al.* 2008. *Blood* 112:1109. [PubMed](#)
24. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
25. Norian LA, *et al.* 2009. *Cancer Res.* 69:3086. (FC) [PubMed](#)
26. Baumgartner CK, *et al.* 2010. *J. Immunol.* 184:573. [PubMed](#)
27. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
28. Whiteland J, *et al.* 1995. *J. Histochem. Cytochem.* 43:313. (IHC)
29. Weber GF, *et al.* 2014. *J Exp Med.* 211:1243. [PubMed](#)
30. Ashok A, *et al.* 2015. *Toxicol Sci.* 143:64. [PubMed](#)
31. Price PJ, *et al.* 2015. *J Immunol.* 194:1164. [PubMed](#)
32. Doni A, *et al.* 2015. *J Exp Med.* 212:905. [PubMed](#)
33. Ferreira R, *et al.* 2016. *J Infect Dis.* 213: 669 - 673. [PubMed](#)
34. Peterson VM, *et al.* 2017. *Nat. Biotechnol.* 35:936. (PG)
35. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
36. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Ochiai S, *et al.* 2014. *J Immunol.* 193:2504. [PubMed](#)
2. Bowling S, *et al.* 2020. *Cell.* 181(6):1410-1422.e27. [PubMed](#)
3. Hu J, *et al.* 2019. *Am J Transl Res.* 3.043055556. [PubMed](#)
4. Grigsby SM, *et al.* 2021. *Cancers (Basel).* 13:. [PubMed](#)
5. Yokozeki Y, *et al.* 2021. *Biomed Res Int.* 2021:7988320. [PubMed](#)
6. Boyd DF, *et al.* 2020. *Nature.* 587:466. [PubMed](#)
7. Han X, *et al.* 2017. *Int J Mol Sci.* 10.3390/ijms18050942. [PubMed](#)
8. Elsner R, *et al.* 2015. *PLoS Pathog.* 10: 1004976. [PubMed](#)
9. Domingues AF, *et al.* 2020. *Elife.* 9:e51754. [PubMed](#)
10. Thierry GR, *et al.* 2018. *J Exp Med.* 215:2972. [PubMed](#)
11. Zhu C, *et al.* 2018. *Sci Rep.* 5.113194444. [PubMed](#)
12. Tanimura N *et al.* 2018. *Developmental cell.* 46(5):581-594 . [PubMed](#)
13. Florentin J, *et al.* 2022. *Front Immunol.* 13:882484. [PubMed](#)
14. Schloss MJ, *et al.* 2022. *Nat Immunol.* 23:605. [PubMed](#)
15. Lin YH, *et al.* 2021. *Front Immunol.* 12:626418. [PubMed](#)
16. Guo F, *et al.* 2022. *Front Immunol.* 13:833100. [PubMed](#)
17. Zhou L, *et al.* 2021. *Cell Mol Immunol.* 18:698. [PubMed](#)
18. Wang Y, *et al.* 2022. *Front Immunol.* 12:809896. [PubMed](#)
19. Yokozeki Y, *et al.* 2021. *BMC Musculoskelet Disord.* 22:634. [PubMed](#)
20. Chou H, *et al.* 2011. *Hepatology.* 53:1007. [PubMed](#)
21. Matson CA, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:14342. [PubMed](#)
22. Preglej T, *et al.* 2020. *JCI Insight.* 5(4):. [PubMed](#)
23. Giambra V *et al.* 2018. *Cell stem cell.* 23(5):714-726 . [PubMed](#)
24. Lancaster JN, *et al.* 2019. *Nat Commun.* 10:2220. [PubMed](#)
25. Yu VWC *et al.* 2016. *Cell.* 167(5):1310-1322 . [PubMed](#)
26. Gutiérrez-Gutiérrez Ó, *et al.* 2021. *EMBO Rep.* 22:e52905. [PubMed](#)
27. Sasse C, *et al.* 2022. *Pathogens.* 11:. [PubMed](#)
28. Matsumoto R, *et al.* 2021. *Front Pharmacol.* 12:715752. [PubMed](#)
29. Browning LM, *et al.* 2020. *Cell Rep.* 33:108219. [PubMed](#)
30. Chen J *et al.* 2018. *Cell reports.* 25(12):3393-3404 . [PubMed](#)
31. Bowers E, *et al.* 2018. *Nat Med.* 24:95. [PubMed](#)
32. Yang X, *et al.* 2020. *Blood Sci.* 2:89. [PubMed](#)
33. Periasamy S, *et al.* 2016. *PLoS Pathog.* 12: 1005517. [PubMed](#)
34. Van de Velde L, *et al.* 2016. *Cell Rep.* 17:2247-2258. [PubMed](#)
35. Xu X, *et al.* 2020. *J Cell Biol.* 219:00:00. [PubMed](#)
36. Liu X, *et al.* 2021. *eLife.* 0.416666666666667. [PubMed](#)
37. Yamamoto K, *et al.* 2021. *Cell Reports.* 36(8):109576. [PubMed](#)
38. Li Q *et al.* 2018. *Immunity.* 48(2):258-270 . [PubMed](#)
39. Mann M, *et al.* 2018. *Cell Rep.* 25:2992. [PubMed](#)
40. Zhao M, *et al.* 2019. *Cell Rep.* 26:652. [PubMed](#)
41. Bian Y, *et al.* 2017. *PLoS Pathog.* 13:e1006384. [PubMed](#)
42. Fukushima T, *et al.* 2019. *Cell Rep.* 29:4144. [PubMed](#)
43. Pham THM, *et al.* 2020. *Cell Host & Microbe.* 27(1):54-67.e5.. [PubMed](#)
44. Zong L, *et al.* 2021. *NPJ Aging Mech Dis.* 7:25. [PubMed](#)
45. Ben C, *et al.* 2020. *J Biol Chem.* 295:13965. [PubMed](#)
46. Dey A *et al.* 2019. *The EMBO journal.* 38(7) pii: e100293. [PubMed](#)
47. Suah AN, *et al.* 2021. *J Clin Invest.* 131:.. [PubMed](#)
48. Paiva RS, *et al.* 2021. *Eur J Immunol.* 51:1968. [PubMed](#)
49. Jassinskaja M, *et al.* 2021. *Cell Reports.* 34(12):108894. [PubMed](#)
50. Levine LS, *et al.* 2021. *Immunity.* 54(4):829-844.e5. [PubMed](#)
51. Paiva RA, *et al.* 2021. *Cell Reports.* 35(2):108967. [PubMed](#)

52. Davidson S, *et al.* 2020. Cell Reports. 31(7):107628. [PubMed](#)
53. Ramos CV, *et al.* 2020. Cell Reports. 32(3):107910. [PubMed](#)
54. Wang L, *et al.* 2021. Cancer Immunol Res. 9:348. [PubMed](#)
55. Khiew SH, *et al.* 2020. J Clin Invest. 130:3453. [PubMed](#)
56. Köchl R, *et al.* 2020. Elife. 9:00. [PubMed](#)
57. Hurrell BP, *et al.* 2019. Cell Rep. 29:4509. [PubMed](#)
58. Yu VWC, *et al.* 2017. Cell. 168:944. [PubMed](#)
59. Onodera T, *et al.* 2019. J Immunol. 203:3282. [PubMed](#)
60. Haase C, *et al.* 2022. Nat Methods. 19:1622. [PubMed](#)
61. Lopez DA, *et al.* 2022. Cell Rep. 41:111677. [PubMed](#)
62. Kotaki R, *et al.* 2020. Sci Rep. 10:13554. [PubMed](#)
63. Noah AC, *et al.* 2020. J Appl Physiol (1985). 473:128. [PubMed](#)
64. Derecka M, *et al.* 2020. Nat Immunol. 261:21. [PubMed](#)
65. Dietmar Herndler-Brandstetter *et al.* 2018. Immunity. 48(4):716-729 . [PubMed](#)
66. Vural A, *et al.* 2019. J Immunol. 202:1510. [PubMed](#)
67. Progatzy F, *et al.* 2021. Nature. 599:125. [PubMed](#)
68. Carr M, *et al.* 2016. Proc Natl Acad Sci U S A. 113(52):15024-15029. [PubMed](#)
69. Frodermann V, *et al.* 2019. Nat Med. 25:1761. [PubMed](#)
70. Chauveau A, *et al.* 2020. Immunity. 52:794. [PubMed](#)
71. Schoeler K, *et al.* 2019. FEBS J. 10.1111/febs.14934. [PubMed](#)
72. Lin C, *et al.* 2022. Nat Commun. 13:6869. [PubMed](#)
73. Onodera T, *et al.* 2021. Immunity. 54:2385. [PubMed](#)
74. Perez E, *et al.* 2020. J Immunol. 205:2489. [PubMed](#)
75. Trefzer A, *et al.* 2021. Cell Reports. 34(6):108748. [PubMed](#)
76. Sasaki T, *et al.* 2020. Cell Reports. 28(1):202-217.e7.. [PubMed](#)
77. Dey S, *et al.* 2020. J Immunother Cancer. 8:. [PubMed](#)
78. Yi W, *et al.* 2021. Cell Reports. 34(13):108922. [PubMed](#)
79. Andersen L, *et al.* 2020. Cell Reports. 29(13):4447-4459.e6.. [PubMed](#)
80. Au-Yeung BB, *et al.* 2017. J Immunol. 198:2445. [PubMed](#)
81. Leyva-Castillo JM *et al.* 2019. Immunity. 50(5):1262-1275 . [PubMed](#)
82. Chen Z, *et al.* 2019. J Exp Med. 216:152. [PubMed](#)
83. Sevin M, *et al.* 2018. Nat Commun. 9:1431. [PubMed](#)
84. Galle-Treger L, *et al.* 2020. J Allergy Clin Immunol. 145:502. [PubMed](#)
85. Galle-Treger L, *et al.* 2019. Nat Commun. 10:713. [PubMed](#)
86. Balzano M *et al.* 2019. Cell reports. 26(12):3257-3271 . [PubMed](#)
87. Yang BH, *et al.* 2020. Cell Reports. 27(12):3629-3645.e6.. [PubMed](#)
88. Akkaya B, *et al.* 2017. J Immunol Methods. 441:67. [PubMed](#)
89. Zhai X, *et al.* 2021. Sci Adv. 7:eabk0490. [PubMed](#)
90. Liu G, *et al.* 2022. Ann Transl Med. 10:693. [PubMed](#)
91. Tsuzuki S, *et al.* 2015. Int Immunol. 10.1093/intimm/dxv058. [PubMed](#)
92. Frohner IE, *et al.* 2020. Cell Rep. 30:3171. [PubMed](#)
93. Vasamsetti SB, *et al.* 2018. Immunity. 49:93. [PubMed](#)
94. Duarte D, *et al.* 2018. Cell Stem Cell. 22:64. [PubMed](#)
95. Stofkova A, *et al.* 2021. Int J Mol Sci. 23:. [PubMed](#)
96. Lehrke MJ, *et al.* 2021. Elife. 10:. [PubMed](#)
97. Zeis P, *et al.* 2020. Immunity. 53:775. [PubMed](#)
98. Nasarre P, *et al.* 2021. Cancers (Basel). 13: . [PubMed](#)
99. Adachi Y, *et al.* 2019. Nat Commun. 10:3883. [PubMed](#)
100. Nagashima H *et al.* 2019. Immunity. 51(4):682-695 . [PubMed](#)
101. Oliveira AC *et al.* 2017. eLife. 6 pii: e30883. [PubMed](#)
102. Yousef H, *et al.* 2019. Nat Med. 25:988. [PubMed](#)
103. Chen Z, *et al.* 2020. Cell Death Dis. 11:180. [PubMed](#)
104. Scortegagna M, *et al.* 2020. Nat Commun. 11:99. [PubMed](#)
105. Schönberger K, *et al.* 2022. STAR Protoc. 3:101408. [PubMed](#)
106. Zhang MH, *et al.* 2020. Front Immunol. 11:560. [PubMed](#)
107. Wang Y, *et al.* 2022. Front Immunol. 13:847581. [PubMed](#)
108. Tomimatsu M, *et al.* 2022. Sci Rep. 12:16656. [PubMed](#)
109. Rohrbeck L, *et al.* 2020. Immunol Cell Biol. . [PubMed](#)
110. Roderick J, *et al.* 2014. Proc Natl Acad Sci U S A. 111:14436. [PubMed](#)
111. De Micheli AJ, *et al.* 2020. Cell Rep. 30:3583. [PubMed](#)
112. Stofkova A, *et al.* 2019. Sci Rep. 2.009027778. [PubMed](#)
113. Murata T, *et al.* 2020. Sci Rep. 10:13560. [PubMed](#)
114. Bajaan S, *et al.* 2022. iScience. 25:103732. [PubMed](#)
115. Koide S, *et al.* 2022. iScience. 25:103603. [PubMed](#)
116. Miyauchi K, *et al.* 2021. Nat Commun. 12:3789. [PubMed](#)
117. Zhang C, *et al.* 2018. Cell Res. 28:323. [PubMed](#)
118. Mohrin M, *et al.* 2021. Aging Cell. 20:e13313. [PubMed](#)
119. Rai S, *et al.* 2022. Nat Commun. 13:5346. [PubMed](#)
120. Ma C, *et al.* 2021. J Exp Med. :218. [PubMed](#)
121. Rosnagl S, *et al.* 2016. PLoS Biol. 14: 1002562. [PubMed](#)
122. Matsuzaki Y, *et al.* 2015. Biomed Rep. 1: 91 - 97. [PubMed](#)
123. Säwen P *et al.* 2018. eLife. 7 pii: e41258. [PubMed](#)
124. Yrlid U, *et al.* 2019. J Leukoc Biol. 105:195. [PubMed](#)
125. Luo H, *et al.* 2019. Cell Rep. 26:945. [PubMed](#)
126. Hirota K *et al.* 2018. Immunity. 48(6):1220-1232 . [PubMed](#)
127. Heyde A, *et al.* 2021. Cell. 184(5):1348-1361.e22. [PubMed](#)
128. Arima Y *et al.* 2017. eLife. 6 pii: e25517. [PubMed](#)
129. Teng Y, *et al.* 2021. Mol Ther. 29:2424. [PubMed](#)
130. Young K, *et al.* 2021. Cell Stem Cell. . [PubMed](#)
131. Frohlich J, *et al.* 2020. Aging (Albany NY). 12:20024. [PubMed](#)

132. Johnson JL *et al.* 2018. *Immunity*. 48(2):243-257 . [PubMed](#)
133. Amend A, *et al.* 2021. *Int J Mol Sci*. 22:. [PubMed](#)

RRID AB_312786 (BioLegend Cat. No. 101203)
AB_312787 (BioLegend Cat. No. 101204)

Antigen Details

Structure	Integrin family, associates with integrin β_2 (CD18), 170 kD
Distribution	Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells
Function	Adhesion, chemotaxis
Ligand/Receptor	ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
Cell Type	B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family	Adhesion Molecules, CD Molecules
Antigen References	1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press. 2. Springer TA. 1994. <i>Cell</i> 76:301. 3. Coxon A, <i>et al.</i> 1996. <i>Immunity</i> 5:653.
Gene ID	16409 3684


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse/human CD11b, Biotin anti-mouse/human CD11b, FITC anti-mouse/human CD11b, PE anti-mouse/human CD11b, PE/Cyanine5 anti-mouse/human CD11b, Purified anti-mouse/human CD11b, PE/Cyanine7 anti-mouse/human CD11b, Alexa Fluor® 488 anti-mouse/human CD11b, Alexa Fluor® 647 anti-mouse/human CD11b, Alexa Fluor® 700 anti-mouse/human CD11b, Pacific Blue™ anti-mouse/human CD11b, APC/Cyanine7 anti-mouse/human CD11b, PerCP/Cyanine5.5 anti-mouse/human CD11b, PerCP anti-mouse/human CD11b, Brilliant Violet 421™ anti-mouse/human CD11b, Brilliant Violet 570™ anti-mouse/human CD11b, Brilliant Violet 605™ anti-mouse/human CD11b, Brilliant Violet 650™ anti-mouse/human CD11b, Brilliant Violet 711™ anti-mouse/human CD11b, Brilliant Violet 785™ anti-mouse/human CD11b, Brilliant Violet 510™ anti-mouse/human CD11b, Ultra-LEAF™ Purified anti-mouse/human CD11b, Purified anti-mouse/human CD11b (Maxpar® Ready), Alexa Fluor® 594 anti-mouse/human CD11b, PE/Dazzle™ 594 anti-mouse/human CD11b, APC/Fire™ 750 anti-mouse/human CD11b, TotalSeq™-A0014 anti-mouse/human CD11b, Brilliant Violet 750™ anti-mouse/human CD11b, TotalSeq™-B0014 anti-mouse/human CD11b, TotalSeq™-C0014 anti-mouse/human CD11b, Spark NIR™ 685 anti-mouse/human CD11b, PE/Fire™ 640 anti-mouse/human CD11b, Spark YG™ 593 anti-mouse/human CD11b, Spark YG™ 570 anti-mouse/human CD11b, PE/Fire™ 810 anti-mouse/human CD11b, APC/Fire™ 810 anti-mouse/human CD11b Antibody, Spark Blue™ 550 anti-mouse/human CD11b, Spark UV™ 387 anti-mouse/human CD11b

Product Data



C57BL/6 mouse bone marrow cells were stained with biotinylated CD11b (clone M1/70) (filled histogram) or rat IgG2b, κ isotype control (open histogram), followed by Sav-PE (gated on total cells).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587